The acute phase reaction explains only a part of initially elevated factor VIII: C levels: A prospective cohort study in patients with venous thrombosis

Tichelaar, V., Mulder, A., Kluin-Nelemans, H. & Meijer, K., Feb-2012, In : Thrombosis Research. 129, 2, p. 183-186 4 p.

Research output: Contribution to journalArticleAcademicpeer-review

Copy link to clipboard


  • The acute phase reaction explains only a part of initially elevated factor VIII

    Final publisher's version, 200 KB, PDF document


We determined in a prospective cohort of patients treated with vitamin K antagonists for venous thrombosis, the course of factor VIII (FVIII: C), C-reactive protein (CRP) and fibrinogen levels, to assess the influence of the acute phase reaction on FVIII: C levels. Second, we hypothesized that patients with preceding infectious symptoms might have higher levels of FVIII: C at baseline than patients without those.

We included 75 patients. Blood was sampled at baseline, once during treatment (t=1) and at the end of treatment (t=2). Mean levels of FVIII: C were 207, 186 and 175 IU/dL (p for trend 0.003) at baseline, t=1 and t=2 respectively. Eight-eight percent of patients had an elevated FVIII: C at baseline, 75% at t=1 and 72% at t=2 (p for trend 0.045). Mean levels of FVIII: C were not different in patients with or without preceding infectious symptoms (206 versus 205 IU/dL respectively). A baseline CRP level below 62 mg/L could best distinguish between patients who will keep an elevated FVIII: C and those who will drop below 150 IU/dL. We conclude that FVIII: C levels are partially influenced by the acute phase reaction, especially in patients who keep a persistent elevated FVIII: C during treatment.

Preceding infectious symptoms did not influence baseline FVIII: C levels. (C) 2011 Elsevier Ltd. All rights reserved.

Original languageEnglish
Pages (from-to)183-186
Number of pages4
JournalThrombosis Research
Issue number2
Publication statusPublished - Feb-2012


  • Factor VIII, Venous thrombosis, CRP, Acute phase reaction, Vitamin K antagonists, DEEP-VEIN THROMBOSIS, THROMBOEMBOLISM, INFECTION, RISK

ID: 5485130